Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

JPMorgan Gains Regulatory Approval In China Eyes Expansion – $JPM $DIA $INVO

By John F. Heerdink, Jr.

Reportedly, JPMorgan Chase & Co (JPM) has acquired Chinese regulatory approval to expand operations in the country as China encourages expansion by foreign companies after lifting its restrictive COVID-19 policies. China is eagerly speeding up the process of granting permission to foreign institutions in order to boost the confidence of overseas investors as the economy is reviving from the pandemic. The China Securities Regulatory Commission informed that the bank’s asset management unit will take full ownership of China International Fund Management Co. (CIFM) with 49% stake The approval came more than two years after the U.S. bank had applied to buy out CIFM, in 2020.

“Our strategic goal is to significantly grow JPMAM China to become the leading foreign asset manager in China and contribute to JPMAM becoming the leading manager of China assets to global investors,” stated Dan Watkins, its Asia Pacific chief executive officer.

China International Fund Management Co. (CIFM) informed that JPMorgan would be operating under the JPMorgan Asset Management (JPMAM) brand and its China private fund unit would also be integrated into JPMAM China consolidating onshore operations.

JPMorgan Chase & Co (JPM) is a global financial service leader in investment banking, financial services for consumers and businesses, financial transaction processing, asset management, and commercial banking. To learn more about JPMorgan Chase & Co. (JPM) and to continue to track its progress please visit the Vista Partners JPMorgan Chase & Co. Coverage Page.


Fertility rates have hit a record low in the United States. The latest US government fertility statistics come from 2019, and they estimate there were 58.2 births year per 1,000 women of childbearing age (defined by the CDC as women between ages 15 and 44).

If you have ever struggled with infertility issues, or know someone who has, you are probably well aware of how demoralizing it can be. Imagine for a moment spending thousands of dollars and months of intensive medical procedure only to end up empty handed, exhausted, sad, and defeated because after all of that time, work, and money, you still don’t have a baby. That’s an incredibly difficult situation, and it’s becoming more common each passing year. Likewise, the need for more effective, less invasive infertility treatment options is increasing with each passing year. This is the sole focus of medtech company INVO Bioscience (NASDAQ: INVO). Learn more by reading the following story that we published recently. 

INVO Bioscience (NASDAQ: $INVO), A Company Seeking To Address A Massively Underserved Fertility Market

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also provides select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives. 

Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
(Read Original Story: UPDATE 3-JPMorgan, Standard Chartered win approval to expand in China in Reuters)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us